
T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations
Fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) improved outcomes vs chemotherapy regardless of baseline PI3K/AKT, ESR1, or BRCA1/2 status in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer previously …